Similar Papers

Paper Title
Journal
Date
Author
Randomized Phase 2 Trial of Ofatumumab and Bendamustine Versus Ofatumumab, Bendamustine, and Bortezomib Induction and Maintenance Therapy in Patients (pts) with Previously Untreated High Risk Follicular Lymphoma (FL): Results from CALGB 50904 (Alliance)
Kristie A Blum ... Nancy L Bartlett
Blood | VOL. 130
Kristie A Blum, et. al.Kristie A Blum ... Nancy L Bartlett
25 Jun 2021
Evaluation of the Different Stratification Models for POD24 Prediction in Patients with Follicular Lymphoma
Wei Wu ...
Blood | VOL. 136
Wei Wu, et. al.Wei Wu ...
05 Nov 2020
Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials
Carla Casulo ... Christopher Flowers
Blood | VOL. 130
Carla Casulo, et. al.Carla Casulo ... Christopher Flowers
25 Jun 2021
The PRIMA-Prognostic Index (PI) Is Valid in Follicular Lymphoma (FL) Patients with Rituximab Chemo-Free First-Line Treatment
Eva Kimby ... Björn Östenstad
Blood | VOL. 132
Eva Kimby, et. al.Eva Kimby ... Björn Östenstad
29 Nov 2018
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements
Qiudan Shen ... Shimin Hu
Blood | VOL. 145
Qiudan Shen, et. al.Qiudan Shen ... Shimin Hu
06 Feb 2025
The dark zone of CNS relapse in DLBCL
Kieron Dunleavy
Blood | VOL. 145
Kieron DunleavyKieron Dunleavy
06 Feb 2025
Impact of new medications on the treatment of Immune TTP.
Marie Scully ... William A Lester
Blood | VOL. -
Marie Scully, et. al.Marie Scully ... William A Lester
06 Feb 2025
No exit: targeting RNA export in T-cell malignancy
Katherine L B Borden
Blood | VOL. 145
Katherine L B BordenKatherine L B Borden
06 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.